(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 0.33% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 8.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.12%.
10x Genomics's revenue in 2025 is $624,662,000.On average, 8 Wall Street analysts forecast TXG's revenue for 2025 to be $76,424,070,141, with the lowest TXG revenue forecast at $75,862,703,375, and the highest TXG revenue forecast at $76,823,146,625. On average, 8 Wall Street analysts forecast TXG's revenue for 2026 to be $74,567,828,860, with the lowest TXG revenue forecast at $73,006,000,375, and the highest TXG revenue forecast at $77,130,981,000.
In 2027, TXG is forecast to generate $82,129,964,983 in revenue, with the lowest revenue forecast at $77,313,588,351 and the highest revenue forecast at $85,908,077,834.